Molecular and histologic characteristics of pseudoprogression in diffuse gliomas

[1]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[2]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[3]  A. Omuro,et al.  Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence , 2015, American Journal of Neuroradiology.

[4]  Qun Wang,et al.  Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis. , 2014, European journal of radiology.

[5]  E. Leuthardt,et al.  Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas. , 2014, Neuro-oncology.

[6]  G. Hutter,et al.  IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. , 2013, Neuro-oncology.

[7]  H. Larsson,et al.  Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis , 2013, Neuroradiology.

[8]  D. Born,et al.  Pseudoprogression: Relevance With Respect to Treatment of High-Grade Gliomas , 2011, Current treatment options in oncology.

[9]  J. Cairncross,et al.  Population-Based Study of Pseudoprogression after Chemoradiotherapy in GBM , 2009, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[10]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[11]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[13]  P. Box.  Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression , 2005 .

[14]  Susan M. Chang,et al.  18‐fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma , 1997, Cancer.